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OBJECTIVES: To estimate the cost-effectiveness impact of the French gatekeeping         
system on chronic patient treated with inhaled corticosteroids (ICS). The study ques-
tion is: Can an incentive economic system as the French gatekeeping (“coordinated 
care pathway”-CCP, August 2004 French Health Insurance reform) have a signiﬁcant 
cost-effectiveness impact, from the French Health insurance perspective. METHODS: 
A working group has been set up, in region Centre, to produce a retrospective Health 
insurance database comparative study. A total of 290 patients in each group were 
included (e.g. the totality of the non-gatekeeping group available in the database), men 
and women, from 16 to 50 years old, treated with ICS over a minima period of three 
consecutive months. The propensity score method (PS) was used in order to reduce 
selection bias from 12 covariates and a semi-Markovian decision model was per-
formed for comparing costs and effectiveness results between treated group and base-
line group, based on these matched individuals. RESULTS: According to the propensity    
score method based on 12 covariates included in the matching algorithm, a 10,000 
individuals bootstrap simulation gave an incremental cost-effectiveness ratio (ICER) 
equal to a49,084 (a48,537; a49,632) per additional patient with a well-controlled 
respiratory disease. The semi-Markovian model, based on these groups matched, 
estimates on one-year horizon a 10,000 bootstrap ICER equal to a34,640 (CI95%: 
[a34,246; a35,033]). To go further, based on the Briggs et al ﬁndings measuring the 
relationship between respiratory disease well controlled or not and QALYs, the new 
ICER ranges from 30,468 euros to 44,157 euros per QALY gained, thus included in 
the European Economic Community thresholds deﬁned by the World Health Organi-
zation (($200023,927 to $200071,781). CONCLUSIONS: This retrospective study on    
annual observational data has shown that the coordinated care pathway strategy is 
cost-effective in the management of chronic patients treated with inhaled corticoster-
oids, from the French Health insurance perspective.
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THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING 
CESSATION IN POLAND
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OBJECTIVES: The aim of the analysis was to estimate the costs and effectiveness of 
varenicline versus existing smoking cessation strategies in Poland. METHODS: A 
Markov model, the Beneﬁts of Smoking Cessation on Outcomes (BENESCO) con-
structed in MS Excel® was used in the analysis. The smoking cessation strategies were 
varenicline, bupropion, nicotine replacement therapy (NRT), unaided cessation and 
placebo. The target population consisted off adult smokers and the time horizon in 
the model was lifelong. The analysis was performed from both payers’ perspective 
(National Heath Fund and patient). The costs and beneﬁts were discounted at 5% 
and 3.5% annual rate respectively. The utilities for the included smoking related 
disease were sourced from the published literature. The quality adjusted life-years 
(QALY), life years gained (LYG), additional smoking cessation case and additional 
avoidance of chronic obstructive lung disease (COPD) were used to estimate effective-
ness of treatment strategies. A probabilistic and univariate sensitivity analysis was 
performed to estimate variability of the obtained results relative to used data. 
RESULTS: Cost of gaining one additional QALY using varenicline versus bupropion, 
NRT, unaided cessation or placebo was respectively 8,750 PLN; 6,140 PLN; 8,827 
PLN and 14,130 PLN. Cost of receiving one additional LYG using varenicline versus 
bupropion, NRT, unaided cessation or placebo was 12,360 PLN; 8,673 PLN; 12,469 
PLN and 19,961 PLN. Cost of one additional smoking cessation case using varenicline 
versus existing smoking cessation strategies was 6,260 PLN to 10,247 PLN and costs 
of one avoidance of COPD case was 27 PLN to 62 PLN. CONCLUSIONS: Results 
of the analysis indicate that varenicline is more effective and more expensive than 
alternative options for smoking cessation. Incremental cost-effectiveness ratios are 
below the acceptable threshold, therefore the varenicline can be considered as highly 
cost-effective treatment.
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OBJECTIVES: To estimate the cost-effectiveness impact of the French gatekeeping         
system on chronic patient treated with inhaled corticosteroids (ICS). The study ques-
tion is: Can an incentive economic system as the French gatekeeping (“coordinated 
care pathway”-CCP, August 2004 French Health Insurance reform) have a signiﬁcant 
cost-effectiveness impact, from the Health care system perspective. METHODS: A 
retrospective Health insurance database comparative study was performed. A total of 
290 patients in each group were included (e.g. the totality of the non-gatekeeping 
group available in the database), men and women, from 16 to 50 years old, treated 
with ICS over a minima period of three consecutive months. The propensity score 
method (PS) was used in order to reduce selection bias from 12 covariates and a 
semi-Markovian decision model was performed for comparing costs and effectiveness 
results between treated group and baseline group, based on these matched individuals. 
RESULTS: The semi-Markovian model, based on these groups matched, estimates on          
one-year horizon a 10,000 bootstrap incremental cost-effectiveness ratio (ICER) equal 
to a33,579 (CI95%: [a33,197; a33,960]) per QALY gained. This result is a relevant 
decisional criterion which is lower than the thresholds (1 to 3 GDP per capita) recom-
mended by the World Health Organization ($200023,927 to $200071,781 for the Euro-
pean Economic Community, region A). CONCLUSIONS: This retrospective study   
on annual observational data has shown that the French gatekeeping system is cost-
effective in the management of patients with chronic respiratory disorder, from the 
health care system perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of a grass allergen immunotherapy 
tablet, Grazax (ALK-Abelló A/S) in combination with symptomatic medications com-
pared to the standard care of symptomatic medications alone for the treatment of 
grass pollen induced rhinoconjunctivitis. The analysis focuses on children, either with 
or without co-existing asthma, for the German setting. METHODS: The two treat-
ment options were evaluated in terms of costs and health outcomes using a decision 
tree approach. The analysis was undertaken from the payer’s perspective, with only 
direct costs included in the base case. The model followed a cohort of 1000 hypotheti-
cal children over nine years in the reference case. Continuous use of Grazax was 
modelled, with the effects of treatment captured in terms of symptom management, 
resource utilisation and allergic asthma development. Data inputs were drawn from 
published studies, databases and published clinical trials. RESULTS: The use of 
Grazax plus symptomatic medications compared to standard care showed an improve-
ment in patient outcomes; 6.92 QALYs as opposed to 6.82 QALYs over the nine-year 
time horizon. The total cost per patient treated with Grazax was a4117 compared to 
a1,502 for standard care. The resulting incremental cost per QALY is a25,900. The 
QALY gains are a result of increased quality of life related to effective symptom 
management and the reduction in allergic asthma development. Sensitivity analysis 
carried out around key parameters shows that the results estimated by the model 
remain robust. CONCLUSIONS: The analysis found Grazax treatment to have an 
incremental cost per QALY which falls below commonly accepted willingness to pay 
thresholds. Therefore, Grazax is a cost-effective option for the treatment of grass 
pollen induced rhinoconjunctivitis for children in Germany.
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OBJECTIVES: To develop a Markov model for health-economic evaluations of COPD 
in Germany that allows estimating the cost-effectiveness of interventions, and to 
demonstrate the applicability of the model by evaluating a smoking cessation program 
compared with usual care. METHODS: A seven-stage Markov model (disease stages 
I to IV according to GOLD classiﬁcation, post-surgery, post-transplantation and 
death) was developed to conduct a cost-utility analysis from the societal perspective 
with a time horizon of 60 years. Exacerbations were subclassiﬁed into mild, moderate 
and severe. Stage-speciﬁc probabilities (for smokers and ex-smokers), utilities and 
costs were estimated based on German data where possible. Uni- and multivariate as 
well as probabilistic sensitivity analyses were conducted to assess the robustness of 
the results. A discount rate of 3% was applied to costs and effects. RESULTS: The 
smoking cessation program was the dominant strategy compared with usual care, as 
it resulted in an increase in health effects of 0.5 QALYs and a cost reduction of a1000. 
Sensitivity analyses showed that uncertainty associated with the model result was 
mostly due to the lack of evidence for costs in early disease stages. CONCLUSIONS: 
The model allows estimating the long-term cost-effectiveness of interventions for 
COPD from a societal perspective in Germany. The smoking cessation program evalu-
ated exemplarily was more effective than usual care as well as cost-saving. Although 
the majority of patients suffer from mild or moderate COPD, data on resource use in 
Germany are lacking for these early stages. These data are needed to assess the societal 
burden of the disease and the cost-effectiveness of interventions.
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OBJECTIVES: Omalizumab is an innovative treatment for difﬁcult-to-treat allergic        
asthma. The mechanism of action of this type of treatment relies on impeding the 
binding of IgEs to their cellular receptor, thus blocking the inﬂammatory cascade. 
Objective of this study is to assess real-world clinical and economical outcomes associ-
ated to add-on omalizumab in difﬁcult-to-treat allergic asthmatics. METHODS: In the  
